Check for updates

OPEN ACCESS

EDITED BY Brian J. Mickey, The University of Utah, United States

REVIEWED BY Naseem Akhtar Qureshi, Al-Falah University, India Peter S. Micalos, Charles Sturt University, Australia

*CORRESPONDENCE Jeremy Seymour ⊠ jerry.seymour8151@gmail.com Nigel Mathers ⊠ n.mathers@sheffield.ac.uk

RECEIVED 24 September 2023 ACCEPTED 26 December 2023 PUBLISHED 10 January 2024

CITATION

Seymour J and Mathers N (2024) Placebo stimulates neuroplasticity in depression: implications for clinical practice and research. *Front. Psychiatry* 14:1301143. doi: 10.3389/fpsyt.2023.1301143

COPYRIGHT

© 2024 Seymour and Mathers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Placebo stimulates neuroplasticity in depression: implications for clinical practice and research

Jeremy Seymour¹* and Nigel Mathers²*

¹Retired Consultant Psychiatrist, Rotherham Doncaster and South Humber NHS Trust, Rotherham, United Kingdom, ²Emeritus Professor, Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom

Neither psychological nor neuroscientific investigations have been able to fully explain the paradox that placebo is designed to be inert in randomized controlled trials (RCTs), yet appears to be effective in evaluations of clinical interventions in all fields of medicine and alternative medicine. This article develops the Neuroplasticity Placebo Theory, which posits that neuroplasticity in fronto-limbic areas is the unifying factor in placebo response (seen in RCTs) and placebo effect (seen in clinical interventions) where it is not intended to be inert. Depression is the disorder that has the highest placebo response of any medical condition and has the greatest potential for understanding how placebos work: recent developments in understanding of the pathophysiology of depression suggest that fronto-limbic areas are sensitized in depression which is associated with a particularly strong placebo phenomenon. An innovative linkage is made between diverse areas of the psychology and the translational psychiatry literature to provide supportive evidence for the Neuroplasticity Placebo Theory. This is underpinned by neuro-radiological evidence of frontolimbic change in the placebo arm of antidepressant trials. If placebo stimulates neuroplasticity in fronto-limbic areas in conditions other than depression - and results in a partially active treatment in other areas of medicine - there are far reaching consequences for the day-to-day use of placebo in clinical practice, the future design of RCTs in all clinical conditions, and existing unwarranted assertions about the efficacy of antidepressant medications. If fronto-limbic neuroplasticity is the common denominator in designating placebo as a partially active treatment, the terms placebo effect and placebo response should be replaced by the single term "placebo treatment."

KEYWORDS

neuroplasticity, placebo, depression, mechanism of action, fronto-limbic circuits

Introduction

Definitions in placebo are important, and this article initially uses terms agreed by international consensus in 2018 (1). This consensus confirms a paradoxical difference between placebo response and placebo effect. Placebo response applies exclusively to clinical trials, where placebo is used on the basis that it should be as inert as possible and have no clinical consequences, to test the effect size of a defined intervention by determining the difference between the inert placebo and the active treatment.

By contrast, placebo effect refers to clinical interventions which are not intended to be inert: such placebo effects have been used (2), either knowingly or unknowingly, by

clinicians to help patients recover since the time of Hippocrates and have a substantial impact on outcomes in clinical care (3), particularly depression (4). There is also a general consensus that it is ethically justifiable to use placebo effects in clinical practice to help patients, provided no subterfuge is involved and the use of placebo is discussed (1, 5).

Placebo response has been studied far more than placebo effect, because of the huge volume of randomized controlled trial (RCT) evidence available from assessment of medical interventions. The quest to find factors (mediators or moderators) that predict placebo response has proved elusive (6).

Depression in particular provides an opportunity to study placebo, since placebo response is known to be high in RCTs of antidepressant treatments, at all levels of depression severity (7, 8). However, depression is a multifaceted condition in which it is difficult to construct pure RCTs to assess treatment outcomes due to difficulties in blinding raters and subjects. In addition, trials of both antidepressant medication and psychological therapy, the two mainstays of treatment, have been subject to accusations of bias because of vested interests (9, 10). This does not detract from the robust finding in the literature that the placebo response is consistently higher in antidepressant trials than in any other medical or psychiatric condition, accounting for approximately 70% of observed improvement in antidepressant trials (11) compared with approximately 50% of observed improvement in all other conditions (12, 13).

Traditional explanations for this difference are that depression is a condition that attracts a high placebo response; or that people who are susceptible to depression are intrinsically likely to be placebo responders; or that there is regression to the mean (14) (regression to the mean arises in one sample of a random variable is extreme, the next sampling of the random variable is likely to be closer to its mean). However, there is little evidence to support any of these explanations, which are laden with value judgments regarding depressed patients.

Neuroplasticity is a topic that has dominated academic publications in translational psychiatry over the last two decades. Neuroplasticity is defined as the ability of the central nervous system to change its activity in response to intrinsic or extrinsic stimuli by reorganizing its structure, functions or connections (15).

In 2016, Rief et al. (16) from the discipline of academic psychology introduced the hypothesis that placebo effect and placebo response trigger neuroplasticity in depression and psychosis, such that placebo is in itself a partially active treatment. This radical hypothesis, if confirmed, has far reaching consequences for interpretation of all clinical trials, particularly those for depression treatment, as well as for the use of placebo to help patients in clinical practice.

This narrative review examines interactions between depression, placebo, and neuroplasticity, and provides updated evidence that placebo itself induces neuroplasticity. The association between neuroplasticity and placebo are referred to in this article as the Neuroplasticity Placebo Theory, and the evidence is drawn from the rapidly developing field of translational psychiatry which lends support to the hypothesis that placebo stimulates neuroplasticity.

This article is in four sections. Firstly, modern thinking on how placebo works is described. Secondly, evidence is examined that neuroplasticity underpins the pathogenesis of dysfunctional frontolimbic circuits in depression. Thirdly, studies are referenced which provide supportive evidence that stimulating neuroplasticity is a common denominator in all treatment modalities of depression, including psychological therapies. Fourthly, the smaller evidence base that placebo stimulates neuroplasticity is examined. Finally, if it is accepted and established that placebo does indeed induce neuroplasticity, the implications for clinical research and clinical practice are considered in the discussion section.

Section 1: neuropsychology and neuroscience underpinning placebo

Since placebo was described 70 years ago (17), there have been repeated attempts to apply scientific rigor to its puzzling properties (18). The last 20 years have seen incremental advances in a wide range of disciplines, but have not provided a cogent unifying scientific explanation for the mechanisms underlying placebo, until now.

Advances in psychological theories of placebo

Academic psychology has evoked learning theory, classical conditioning, and expectancy as the context for verbal, contextual and social cues generating treatment expectancies (19, 20). For example, many of us associate taking medication with feeling better from our childhood experiences, so expectation is created that taking medication in a drug trial will help, even if it is a sugar pill placebo.

Learning theory, conditioning and expectancy have been regarded as competing theories to explain placebo, although Colloca and Miller (20) have suggested amalgamating these ideas into a single integrated learning model. Furthermore, Ashar et al. (21) have developed a sophisticated 'effective appraisal account' model of placebo in which the brain incorporates precognitive learnt associations into appraisals of future wellbeing. Thus appraisals shape associative learning, based on what has been learnt from experience. Allying this to neuroradiological changes in the brain during a placebo condition in mood disorders, pain, and Parkinson's disease, Ashar et al. (21) found that appraisals reliably engaged the default mode network as centrally important in the placebo condition. The default mode network represents areas that are more active during times of brain quiescence compared to cognitive activity, and usually involves fronto-limbic areas including the left dorsolateral prefrontal cortex (DLPFC), the anterior cingulate cortex and ventral striatum. These are the anatomical areas associated with the brain making appraisals during placebo, and as abnormalities in these areas are also evident in depression, a co-location link between depression and placebo is invoked, potentially explaining why placebo response is so high in trials of antidepressant treatment (22). However, this is an association rather than causation, and while it has been suggested that placebo is a neuromodulator in depression (23), this remains unproven.

The study of Ashar et al. (21) is an important advance in the understanding of placebo from a psychological perspective, but, as the authors acknowledge, it fails to explain why placebos persist and do not naturally extinguish (24). A remarkable feature of both placebo effect and placebo response is that they persists for several weeks (24, 25). A limitation of all psychological theories of placebo is therefore that there is no ready explanation for persistence, unless an additional process such as neuroplasticity is invoked.

Advances in neurochemical and neuroscientific theories of placebo

Advances in the psychological understanding of placebo have been paralleled by increasing knowledge of the neuroscientific basis of placebo. Molecular and genetic contributions to placebo have been delineated, for example, through the reproducible neurochemical changes in dopamine levels, monoamines and opioids (26), demonstrated in Parkinson's disease (27), mood disorders (28) and pain states (29). As in psychological theories of placebo, the same neuroanatomical brain regions are involved, principally the default mode network. It is possible that the default mode network is sensitized to respond to placebo influences in a different manner in CNS disorders.

The focus on neurochemical changes in Parkinson's disease, mood disorders and pain states has its limitations, as it is not clear whether the results are transferrable to non CNS disorders, for example, placebo influences in asthma or dermatitis.

Readers interested in the neuroscience underpinning placebo are referred to the reviews by Cai and He (30), and Wager and Atlas (31), but it can be concluded that solely neuroscientific studies cannot completely answer the question: "how can placebo effect and placebo response be explained in diverse medical disorders that are outwith the CNS?"

Summary

While some authors have sought to explain placebo in purely psychological terms (7, 20), or in purely neuroscientific terms (32), most literature reflects a general consensus that psychological and neuroscientific explanations are complementary and of equal importance. Explaining placebo requires contributions from diverse areas of literature (20, 33, 34), but it is only by invoking an additional process such as neuroplasticity that creates the potential to bridge the gap between psychological and neuroscientific explanations of placebo.

Section 2: noxious humoral stimuli in depression trigger dysfunctional neuroplasticity

The monoamine hypothesis of depression was first articulated in 1965 (35) and suggested that systemically secreted hormones induced by stress interacted with and induced change in brain neurochemicals, principally monoamines, via the Hypothalamic–Pituitary–Adrenal (HPA) axis. Tricyclic antidepressants and monoamine oxidase inhibitors, which were discovered by serendipity, were thought to exert their mode of action by correcting this chemical imbalance. With the advent of functional Magnetic Resonance Imaging (fMRI) and Positron Emission Topography (PET) it became clear that depression at the more severe end of the spectrum is a disorder of structure as well as function, with marked abnormalities demonstrable in fronto-limbic circuits (36) that are reversible with treatment (37), i.e., they are not just epiphenomena.

Neuroplasticity has been unequivocally demonstrated to be disrupted in mood disorders and animal models of stress (38).

Chronic stress precipitates and exacerbates depression via neuroplasticity, but more importantly antidepressant treatments (in the broadest sense) stimulate opposing effects to enhance neuroplasticity and reverse the changes induced by stress. While the exact role of neuroplasticity in the genesis and management of depression (and other overlapping disorders such as anxiety and psychosis) has yet to be elucidated, neuroplastic change demonstrably effects both structure and function in human and animal models of depression (15).

The monoamine hypothesis has therefore been superseded by the formulation that depression is a disorder of brain neuroplasticity (15, 39), probably triggered by over-activity of the HPA axis.

Furthermore, if abnormal fronto-limbic circuits specific to depression have formed, the aim of all antidepressant treatment is firstly to disrupt the abnormal circuits and then to promote their replacement with "normal" circuitry, via a process of neuroplasticity (40). This model complements psychological theories on the genesis and management of depression (41).

Neuroplasticity has now been described in structural terms, with direct evidence of stimulation of new dendritic spine growth and interconnections which can be observed *in vivo* (42); in functional terms, through stimulation of new synaptic morphology equivalent to "upregulation of receptors" (43); and in biochemical terms through description of cellular mechanisms. The biochemical link is particularly important, as blockade of the N-methyl-D-Aspartate receptor on glutamate neurons stimulates release of Brain Derived Neurotrophic Factor (44), which increases synaptogenesis and dendritogenesis (42). There is also some evidence that blood BDNF levels-as a marker for neuroplastic activity-are correlated with antidepressant response (45).

In summary, it has been known since the last century that neurochemical explanations of both the pathogenesis and management of depression do not explain the whole picture, and links between monoamine abnormalities and neuroplasticity are increasingly evident (46). The conclusion of more than 20 years of translational and clinical research is that adverse neuroplasticity is centrally involved in the pathogenesis of depression, resulting in aberrant resting state functional connectivity in fronto-limbic circuits subserving emotion, reward processing, and executive functioning. This approach is consistent with psychological theories of depression such that neuroplasticity and psychological theories can now be integrated (41). The corollary is that stimulating neuroplasticity is also now a prime target for all antidepressant treatment interventions (40): this has been elegantly summarized in the reviews by Pittenger and Duman (38) and Duman and Price (41).

Section 3: neuroplasticity is a universal brain process that is fundamental to all antidepressant treatment

The explosion of translational research into neuroplasticity, and the ability to track it through neuro-radiological techniques (47), has clarified the central role of neuroplasticity in both neurodevelopment and central nervous system (CNS) repair. At an early stage of postnatal human brain development, glutamate and gamma-aminobutyric acid (GABA) are the only neurochemicals identifiable in the CNS: glutamate and GABA are therefore centrally involved in stimulating physiological neuroplasticity (48). This applies throughout the lifespan, with neuroplasticity playing a central role in maintenance of brain function throughout. Some fronto-limbic brain regions are more susceptible to neuroplastic change than other brain regions, for example the hippocampus is particularly sensitive (49), and can even generate new cells in response to stimuli (neurogenesis), as well as the dendritogenesis and synaptogenesis that are the core of neuroplasticity (42).

Diverse stimuli initiate neuroplasticity in different brain regions over different time frames. Musical training induces neuroplasticity in the dorsal auditory stream region (50). Playing the computer game Super Mario induces neuroplasticity in the right hippocampus, right DLPFC, and bilaterally in the cerebellum (51). Yoga induces gray matter volume change in the left insular, frontal operculum and orbitofrontal cortex (52). Any drug that crosses the blood brain barrier, prescribed or recreational, exerts part of its effect by interacting with receptors and stimulating neuroplasticity (53): it is now routine to be able to track neuroplastic changes in drug development *in vivo* using sophisticated neuroimaging (37, 42, 54). The therapeutic potential of neuroplasticity in many fields of medicine, but particularly psychiatry, has yet to be realized (40, 55).

Depression represents a special case of neuroplasticity for two reasons. Firstly, adverse neuroplastic change has already occurred in the brain in the genesis of depression, with formation of the abnormal circuits demonstrable on fMRI. Secondly, the relevant brain areas in depression are interconnecting pathways between the DLPFC, the limbic system, and the hypothalamus. These pathways are particularly sensitive and susceptible to neuroplastic change. There is now strong evidence that neuroplasticity is centrally involved in the therapeutic action of diverse antidepressant treatment modalities, including electroconvulsive therapy (56, 57), psychological therapy (58), exercise (59), and medication (15, 39, 54).

Much has also been learnt about neuroplasticity in depression from investigating the mode of action of ketamine (39, 54). Ketamine was discovered by serendipity, and the original description noted rapid improvement in depressive symptoms within 45 min in depressed patients coincidentally receiving ketamine as an anesthetic (60). Ketamine is unusual as an anesthetic in exerting its mode of action by interrupting association pathways between the thalamocortical and limbic systems to induce unconsciousness (61)—most other anesthetics work on the reticular activating system—and this anatomical location of site of action is relevant to its antidepressant effects. The speed of antidepressant action of ketamine has revealed two types of neuroplasticity: ionotropic, which acts within hours, and metabotropic, acting over weeks (62).

The process of improving clinical outcomes in depression by managing neuroplasticity (15, 39, 54), is now the predominant research avenue for developing novel antidepressant treatments.

Section 4: evidence that placebo stimulates neuroplasticity

Rief et al. (16) first postulated that placebo stimulates neuroplasticity in depression and schizophrenia, based on a decade of psychology research into the placebo response in mental illness, but their hypothesis was rooted in psychological expectation theories of placebo in depression without reviewing the wider context (63). Their observation that placebo stimulates neuroplasticity was from the perspective that treatment context affects psychopharmacological interventions, and, for example, the prescription of antidepressant medication should be accompanied by exercise.

Their hypothesis has subsequently been supported by data from the Establishing Moderators and Biosignatures of Antidepressant response for clinical Care (EMBARC) series of studies, which set out to investigate clinical moderators and biological moderators and mediators of antidepressant response (64). Specifically, the studies compared prospectively a range of markers, including fMRI and cerebral blood perfusion, in an adequately powered trial of patients with Major Depressive Disorder (MDD) who received either sertraline or placebo over an 8-week period. A striking and unexpected finding, not anticipated in the original aims and objectives of the study, was the high response rate of the placebo group, resulting in a negligible effect size for sertraline treatment. Overall, 33% of subjects randomized to the placebo group achieved remission compared to 37% of the active sertraline treated group (65, 66) strongly suggesting that placebo is a partially active treatment in MDD.

The second striking finding of the EMBARC studies was that the group receiving placebo demonstrated cerebral perfusion and functional neuro-radiological change suggestive of neuroplasticity in fronto-limbic areas, albeit in slightly different brain regions to the group receiving sertraline. This unexpected finding prompted some of the EMBARC study group to conduct a systematic review (67) that sought functional neuroimaging correlates of placebo response in subjects with anxiety/depressive disorders. The 12 extracted studies for depression found that in patients where placebo induced antidepressant improvement occurred, this correlated broadly with abnormalities in the default mode network, known to mediate depression (36), with prominent additional activity in the ventral striatum, rostral anterior cingulate cortex, orbitofrontal cortex and particularly in the DLFPC. These brain areas show abnormal activity in depression, so it is a significant finding that similar abnormalities are seen with placebo.


Overall, the findings of the EMBARC series of studies lend support to the hypothesis that placebo stimulates neuroplasticity, a serendipitous finding given the original aims and objectives of the study (64).

Discussion

As with many discoveries in depression, serendipity has played a prominent role. The EMBARC studies provide coincidental data that placebo induces fronto-limbic stimulation of neuroplasticity in MDD patients, lending indirect support to the hypothesis of Rief et al. (16) that placebo stimulates neuroplasticity.

Synthesizing the evidence from the four sections above, the Neuroplasticity Placebo Theory states that placebo effect and placebo response are equivalent, and are active interventions associated with neuroplasticity. The link between psychological and neuroscientific explanations of placebo is that expectation triggers neuroplasticity in fronto-limbic areas that subserve mood, executive functioning and emotion (see Figure 1).

Neuroplasticity is the common denominator, exerting similar measurable neurobiological activity in fronto-limbic areas of the



brain in the different settings of clinical practice and clinical trials. While placebo is active in almost all clinical trials across every medical intervention, it is particularly prominent in trials of depression as fronto-limbic areas are already sensitized by the process of developing depression. The Neuroplasticity Placebo Theory is able to explain the paradox that placebo effect and placebo response apparently differ, and posits that placebo *effect* and placebo *response* are terms that should become redundant, to be replaced by the single term placebo *treatment*.

There is therefore sufficient evidence from the EMBARC studies and the systematic review of Huneke et al. (67) to conclude that placebo is a partially active treatment in depression through stimulation of neuroplasticity. This is the first article to suggest that neuroplasticity is generalizable to all placebo influence, not just depression, and to review evidence that placebo stimulates neuroplasticity.

The Neuroplasticity Placebo Theory potentially has far reaching implications for research and clinical practice.

Firstly, clinicians are using placebo treatment in many interactions with their patients, an intervention that is changing their patients' brain morphology, so clinicians should explain this to patients in the context of the principles of informed consent (1, 5), as with any other treatment intervention. It is unclear if such an explanation to patients would dissipate the benefits of placebo.

Secondly, the Neuroplasticity Placebo Theory suggests that in general all existing RCTs are variably contaminated by bias as placebo response varies with trial conditions. The results of RCTs are not invalidated by this observation because of the power of randomization (14), but should be interpreted with caution. If clinical triallists wish to design RCTs that minimize the placebo treatment influence—and thus provide a better assessment of the effect size—interventions could be delivered remotely rather than via human contact with a research assistant or clinical, and subjects with comorbid depression could be excluded from clinical trials. Thirdly, it is known that placebo treatment persists (24, 25), but it is not known for how long it persists. Future trial design should incorporate longer term follow up of outcomes in order to better determine effect size, and should consider adding mixed methods research (68, 69) to the evaluation of short and long term outcomes.

Finally, specifically for depression trials, depression as a disorder is unique in that there is a relatively large impact on the control arm of RCTs, which may undermine conclusions regarding effect size. Several authors have evoked the small effect size in trials of antidepressant medications to repeatedly assert (7, 9, 70, 71) that

as antidepressants have limited efficacy vs. placebo, they should be replaced by psychological therapy and exercise to treat depression at all levels of severity, and thus avoid the side effects of antidepressants. These opinions are controversial (72), and have generated a disproportionate degree of attention in media and social media (73), and contribute to the potentially harmful decision by many patients with MDD worldwide to refuse antidepressants (74).

The Neuroplasticity Placebo Theory helps to resolve this controversy by clarifying that those authors, who have based their assertions on the outdated concept that depression is caused by a chemical imbalance (70, 71), are asking the wrong question: instead of asking "Why is the effect size so small?," the correct question is "Why is the placebo response so high?," to which the answer is "Neuroplasticity." It can be concluded that the work of Kirsch and Moncrieff has been a major contribution to the literature in drawing the attention of patients, clinicians and commissioners to the importance of psychological therapy and exercise in a stepped model of care (75). However, the sophisticated statistical analysis by Cipriani et al. (76, 77) is more relevant in deciding the place of antidepressants in the management of MDD, since the observations of Kirsch and Moncrieffe on effect size in depression of all grades of severity have been superseded by advances in knowledge of placebo and neuroplasticity (39, 41, 67).

If placebo is a partially active treatment, its place in the management of depression could be tested further by a RCT design for depressed subjects that compares placebo (i.e., a sugar pill in a drug trial setting) with no treatment, if such a trial could be deemed ethically justifiable (78). The persistence of placebo response (24, 25) is supportive evidence for the Neuroplasticity Placebo Theory, which invokes metabotropic neuroplasticity as the explanation for persistence. However, further research is also required into how long the benefits of placebo treatment persist in other medical interventions. More prospective research is needed with long term follow up to clarify if exercise or counseling, which also act on fronto-limbic areas, confer any synergistic benefit to outcomes when combined with other neuroplasticity-inducing antidepressant treatments (40).

This article is a narrative review rather than a critical review, a systematic review, or a meta-analysis. It presents no new data in support of the Neuroplasticity Placebo Theory. As such it is aimed at practicing clinicians and has sought support for the theory by synthesizing ideas and evidence from diverse sources of literature; in particular the novelty of linking the hypothesis of Rief et al. (16) with outcome data from the EMBARC series of studies (65). This

underlines the importance of integrating psychological and neuroscientific formulations, in research as well as clinical practice, to best help patients.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

JS: Writing - original draft. NM: Writing - review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

References

1. Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. *Psychother Psychosom.* (2018) 87:204–10. doi: 10.1159/000490354

2. Linde K, Atmann O, Meissner K, Schneider A, Meister R, Kriston L, et al. How often do general practitioners use placebos and non-specific interventions? Systematic review and Meta-analysis of surveys. *PLoS One.* (2018) 13:e0202211. doi: 10.1371/journal. pone.0202211

3. Thomas KB. General practice consultations: is there any point in being positive? *Br Med J.* (1987) 294:1200–2. doi: 10.1136/bmj.294.6581.1200

4. Brown WA. Placebo as a treatment for depression. *Neuropsychopharmacology*. (1994) 10:265–9. doi: 10.1038/npp.1994.53

5. Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. (2015) 373:8–9. doi: 10.1056/NEJMp1504023

6. Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. *Lancet Psychiatry*. (2015) 2:246–57. doi: 10.1016/S2215-0366(14)00092-3

7. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a Meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med.* (2008) 5:e45. doi: 10.1371/journal. pmed.0050045

8. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level Meta-analysis. *JAMA*. (2010) 303:47–53. doi: 10.1001/jama.2009.1943

9. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The Emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. *Prev Treat.* (2002) 5:523. doi: 10.1037/1522-3736.5.1.523a

10. Scott MJ. Improving access to psychological therapies (Iapt)—the need for radical reform. *J Health Psychol.* (2018) 23:1136–47. doi: 10.1177/1359105318755264

11. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. *Philos Trans R Soc Lond Ser B Biol Sci.* (2011) 366:1879–88. doi: 10.1098/rstb.2010.0394

12. Hafliðadóttir SH, Juhl CB, Nielsen SM, Henriksen M, Harris IA, Bliddal H, et al. Placebo response and effect in randomized clinical trials: Meta-research with focus on contextual effects. *Trials.* (2021) 22:493. Epub 2021/07/28. doi: 10.1186/ s13063-021-05454-8

13. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database Syst Rev.* (2010) 2010:Cd003974. doi: 10.1002/14651858.CD003974. pub3

14. Torgerson DJ, Torgerson CJ. Designing randomised trials in health, education and the social sciences, vol. XV. London: Palgrave Macmillan (2008). 210 p.

15. Albert PR. Adult neuroplasticity: a new "cure" for major depression? J Psychiatry Neurosci. (2019) 44:147–50. doi: 10.1503/jpn.190072

16. Rief W, Barsky AJ, Bingel U, Doering BK, Schwarting R, Wöhr M, et al. Rethinking Psychopharmacotherapy: the role of treatment context and brain plasticity in

Acknowledgments

Thanks to Michael Campbell, Emeritus Professor in Medical Statistics, University of Sheffield, who commented on an earlier draft of this paper with respect to randomisation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

antidepressant and antipsychotic interventions. *Neurosci Biobehav Rev.* (2016) 60:51–64. Epub 2015/12/01. doi: 10.1016/j.neubiorev.2015.11.008

17. Beecher HK. The powerful placebo. J Am Med Assoc. (1955) 159:1602–6. doi: 10.1001/jama.1955.02960340022006

18. Grunbaum A. The placebo concept in medicine and psychiatry. *Psychol Med.* (1986) 16:19–38. doi: 10.1017/s0033291700002506

19. Geers AL, Miller FG. Understanding and translating the knowledge about placebo effects: the contribution of psychology. *Curr Opin Psychiatry*. (2014) 27:326–31. doi: 10.1097/YCO.00000000000082

20. Colloca L, Miller FG. How placebo responses are formed: a learning perspective. *Philos Trans R Soc Lond Ser B Biol Sci.* (2011) 366:1859–69. Epub 2011/05/18. doi: 10.1098/rstb.2010.0398

21. Ashar YK, Chang LJ, Wager TD. Brain mechanisms of the placebo effect: an affective appraisal account. *Annu Rev Clin Psychol.* (2017) 13:73–98. doi: 10.1146/ annurev-clinpsy-021815-093015

22. Brown V, Pecina M. Neuroimaging studies of antidepressant placebo effects: challenges and opportunities. *Front Psych.* (2019) 10:669. doi: 10.3389/fpsyt.2019.00669

23. Burke MJ, Romanella SM, Mencarelli L, Greben R, Fox MD, Kaptchuk TJ, et al. Placebo effects and neuromodulation for depression: a Meta-analysis and evaluation of shared mechanisms. *Mol Psychiatry.* (2022) 27:1658–66. doi: 10.1038/ s41380-021-01397-3

24. Peoples SG. The persistent power of placebo. Nature reviews. *Psychology*. (2022) 1:4. doi: 10.1038/s44159-022-00078-4

25. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. *J Psychiatr Res.* (2008) 42:791–6. doi: 10.1016/j. jpsychires.2007.10.004

26. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human mu-opioid activity during pain. *Proc Natl Acad Sci U S A*. (2007) 104:11056–61. doi: 10.1073/pnas.0702413104

27. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. *Arch Gen Psychiatry*. (2010) 67:857–65. doi: 10.1001/archgenpsychiatry.2010.88

28. Peciña M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, et al. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. *JAMA Psychiatry.* (2015) 72:1087–94. Epub 2015/10/01. doi: 10.1001/jamapsychiatry.2015.1335

29. Krummenacher P, Candia V, Folkers G, Schedlowski M, Schonbachler G. Prefrontal cortex modulates placebo analgesia. *Pain*. (2010) 148:368–74. doi: 10.1016/j. pain.2009.09.033

30. Cai L, He L. Placebo effects and the molecular biological components involved. *Gen Psychiatr.* (2019) 32:e100089. doi: 10.1136/gpsych-2019-100089

31. Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, Learning and Health. *Nat Rev Neurosci*. (2015) 16:403–18. doi: 10.1038/nrn3976

32. Benedetti F. Placebo effects: from the neurobiological paradigm to translational implications. *Neuron*. (2014) 84:623–37. doi: 10.1016/j.neuron.2014.10.023

33. Peiris N, Blasini M, Wright T, Colloca L. The placebo phenomenon: a narrow focus on psychological models. *Perspect Biol Med.* (2018) 61:388–400. doi: 10.1353/ pbm.2018.0051

34. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. *Am J Psychiatry*. (2013) 170:723–33. doi: 10.1176/appi.ajp.2012.12040474

35. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am J Psychiatry*. (1965) 122:509–22. Epub 1965/11/01. doi: 10.1176/ajp.122.5.509

36. Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional Mri in depression unmasks increased connectivity between networks via the dorsal Nexus. *Proc Natl Acad Sci U S A*. (2010) 107:11020–5. doi: 10.1073/pnas.1000446107

37. Wang X, Qin J, Zhu R, Zhang S, Tian S, Sun Y, et al. Predicting treatment selections for individuals with major depressive disorder according to functional connectivity subgroups. *Brain Connect.* (2022) 12:699–710. doi: 10.1089/brain.2021.0153

38. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology*. (2008) 33:88–109. doi: 10.1038/sj. npp.1301574

39. Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: Gaba and glutamate neurotransmitter deficits and reversal by novel treatments. *Neuron.* (2019) 102:75–90. doi: 10.1016/j.neuron.2019.03.013

40. Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging neuroplasticity to enhance adaptive learning: the potential for synergistic somaticbehavioral treatment combinations to improve clinical outcomes in depression. *Biol Psychiatry*. (2019) 85:454–65. doi: 10.1016/j.biopsych.2018.09.004

41. Price RB, Duman R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. *Mol Psychiatry*. (2020) 25:530–43. doi: 10.1038/s41380-019-0615-x

42. Kelsch W, Sim S, Lois C. Watching synaptogenesis in the adult brain. Annu Rev Neurosci. (2010) 33:131–49. doi: 10.1146/annurev-neuro-060909-153252

43. Scott L, Kruse MS, Forssberg H, Brismar H, Greengard P, Aperia A. Selective upregulation of dopamine D1 receptors in dendritic spines by Nmda receptor activation. *Proc Natl Acad Sci U S A*. (2002) 99:1661–4. doi: 10.1073/pnas.032654599

44. Bjorkholm C, Monteggia LM. Bdnf—a key transducer of antidepressant effects. *Neuropharmacology*. (2016) 102:72–9. doi: 10.1016/j.neuropharm.2015.10.034

45. Brunoni AR, Lopes M, Fregni F. A systematic review and Meta-analysis of clinical studies on major depression and Bdnf levels: implications for the role of neuroplasticity in depression. *Int J Neuropsychopharmacol.* (2008) 11:1169–80. doi: 10.1017/S1461145708009309

46. Kraus C, Castren E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity links between molecular, functional and structural pathophysiology in depression. *Neurosci Biobehav Rev.* (2017) 77:317–26. doi: 10.1016/j.neubiorev.2017.03.007

47. Tardif CL, Gauthier CJ, Steele CJ, Bazin PL, Schafer A, Schaefer A, et al. Advanced Mri techniques to improve our understanding of experience-induced neuroplasticity. *NeuroImage*. (2016) 131:55–72. doi: 10.1016/j.neuroimage.2015.08.047

48. Pallotto M, Deprez F. Regulation of adult neurogenesis by Gabaergic transmission: signaling beyond Gabaa-receptors. *Front Cell Neurosci.* (2014) 8:166. doi: 10.3389/fncel.2014.00166

49. Leuner B, Gould E. Structural plasticity and hippocampal function. Annu Rev Psychol. (2010) 61:111-40. doi: 10.1146/annurev.psych.093008.100359

50. Olszewska AM, Gaca M, Herman AM, Jednorog K, Marchewka A. How Musical Training Shapes the Adult Brain: Predispositions and Neuroplasticity. *Front Neurosci.* (2021) 15:630829. doi: 10.3389/fnins.2021.630829

51. Kuhn S, Gleich T, Lorenz RC, Lindenberger U, Gallinat J. Playing super Mario induces structural brain plasticity: gray matter changes resulting from training with a commercial video game. *Mol Psychiatry*. (2014) 19:265–71. doi: 10.1038/mp.2013.120

52. Villemure C, Ceko M, Cotton VA, Bushnell MC. Neuroprotective effects of yoga practice: age-, experience-, and frequency-dependent plasticity. *Front Hum Neurosci.* (2015) 9:281. doi: 10.3389/fnhum.2015.00281

53. Paulzen M, Veselinovic T, Grunder G. Effects of psychotropic drugs on brain plasticity in humans. *Restor Neurol Neurosci.* (2014) 32:163–81. doi: 10.3233/ RNN-139004

54. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. *Annu Rev Med.* (2015) 66:509–23. doi: 10.1146/annurev-med-053013-062946

55. Cramer SC, Sur M, Dobkin BH, O'Brien C, Sanger TD, Trojanowski JQ, et al. Harnessing neuroplasticity for clinical applications. *Brain*. (2011) 134:1591–609. doi: 10.1093/brain/awr039 56. Pirnia T, Joshi SH, Leaver AM, Vasavada M, Njau S, Woods RP, et al. Electroconvulsive therapy and structural neuroplasticity in neocortical, limbic and Paralimbic cortex. *Transl Psychiatry*. (2016) 6:e832. doi: 10.1038/tp.2016.102

57. Seymour J. Commentary and update on the contribution of the Gaba hypothesis to understanding the mechanism of action of electroconvulsive therapy. *J ECT*. (2021) 37:4–9. doi: 10.1097/YCT.00000000000711

58. Collerton D. Psychotherapy and brain plasticity. *Front Psychol.* (2013) 4:548. doi: 10.3389/fpsyg.2013.00548

59. de Sousa Fernandes MS, Ordonio TF, Santos GCJ, Santos LER, Calazans CT, Gomes DA, et al. Effects of physical exercise on neuroplasticity and brain function: a systematic review in human and animal studies. *Neural Plast.* (2020) 2020:8856621-1. doi: 10.1155/2020/8856621

60. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry.* (2000) 47:351-4. doi: 10.1016/s0006-3223(99)00230-9

61. Roberts JR. Pharmacologic adjuncts to intubation In: JR Roberts and JR Hedges, editors. *Roberts and Hedges' clinical procedures in emergency medicine and acute care. 7th* ed. London: Elsevier (2019). 111–26.e3.

62. Crupi R, Impellizzeri D, Cuzzocrea S. Role of metabotropic glutamate receptors in neurological disorders. *Front Mol Neurosci.* (2019) 12:20. doi: 10.3389/fnmol.2019.00020

63. Rief W, Petrie KJ. Can psychological expectation models be adapted for placebo research? *Front Psychol.* (2016) 7:1876. doi: 10.3389/fpsyg.2016.01876

64. Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (Embarc): rationale and design. J Psychiatr Res. (2016) 78:11–23. doi: 10.1016/j.jpsychires.2016.03.001

65. Cooper CM, Chin Fatt CR, Jha M, Fonzo GA, Grannemann BD, Carmody T, et al. Cerebral blood perfusion predicts response to sertraline versus placebo for major depressive disorder in the Embarc trial. *EClinicalMedicine*. (2019) 10:32–41. doi: 10.1016/j.eclinm.2019.04.007

66. Chin Fatt CR, Jha MK, Cooper CM, Fonzo G, South C, Grannemann B, et al. Effect of intrinsic patterns of functional brain connectivity in moderating antidepressant treatment response in major depression. *Am J Psychiatry.* (2020) 177:143–54. doi: 10.1176/appi.ajp.2019.18070870

67. Huneke NTM, Aslan IH, Fagan H, Phillips N, Tanna R, Cortese S, et al. Functional neuroimaging correlates of placebo response in patients with depressive or anxiety disorders: a systematic review. *Int J Neuropsychopharmacol.* (2022) 25:433–47. doi: 10.1093/ijnp/pyac009

68. O'Cathain A, Murphy E, Nicholl J. Why, and how, mixed methods research is undertaken in health services research in England: a mixed methods study. *BMC Health Serv Res.* (2007) 7:85. doi: 10.1186/1472-6963-7-85

69. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ*. (2021) 374:n2061. doi: 10.1136/bmj.n2061

70. Kirsch I. Placebo effect in the treatment of depression and anxiety. *Front Psych.* (2019) 10:407. doi: 10.3389/fpsyt.2019.00407

71. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. *BMJ*. (2005) 331:155–7. doi: 10.1136/bmj.331.7509.155

72. Moller HJ, Bitter I, Bobes J, Fountoulakis K, Hoschl C, Kasper S, et al. Position statement of the European psychiatric association (Epa) on the value of antidepressants in the treatment of unipolar depression. *Eur Psychiatry.* (2012) 27:114–28. doi: 10.1016/j.eurpsy.2011.08.002

73. Kirsch I. The Emperor's new drugs: medication and placebo in the treatment of depression. *Handb Exp Pharmacol.* (2014) 225:291–303. doi: 10.1007/978-3-662-44519-8_16

74. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a Meta-analytic review. *J Clin Psychiatry*. (2013) 74:595–602. doi: 10.4088/JCP.12r07757

75. NICE (National Institute for Health and Care Excellence). *Depression in adults: treatment and management. 29 June 2022.* (2022). National Institute for Health and Care Excellence. Available at: https://www.nice.org.uk/guidance/ng222 (Accessed December 31, 2023).

76. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network Meta-analysis. *BMJ Open.* (2016) 6:e010919. doi: 10.1136/bmjopen-2015-010919

77. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network Meta-analysis. *Lancet.* (2018) 391:1357–66. doi: 10.1016/S0140-6736(17)32802-7

78. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an Fda perspective. *Eur Psychiatry*. (2001) 16:418–23. doi: 10.1016/s0924-9338(01)00600-9